But Allergan has repeatedly refused to engage in talks and has criticized Valeant's business model, saying its results would reflect weak organic growth and questioning whether Bausch + Lomb's growth rates would continue in the third quarter.
In defense, Valeant said Wednesday that it expects to beat consensus revenue estimates for the third quarter when it reports results on Oct. 20, while earnings, excluding restructuring charges, would be stronger than it previously estimated. It added that Bausch + Lomb is expected to post same-store organic growth of more than 10%.
The pharmaceutical company also made public three letters it said reflect its latest conversations with Allergan.
In Monday's letter to Allergan Chief Executive David Pyott, Valeant's chief, J. Michael Pearson, said he wanted to extend an "olive branch" and "take the temperature down" in what has been a heated takeover battle. He also pushed for an in-person meeting between the executives in order to avoid a three-month proxy contest.
Quebec-based Valeant then made public what it called Allergan's same-day response in which Mr. Pyott again called Valeant's bid "grossly inadequate" and said Valeant's business model would destroy shareholder value if applied at Allergan.
Mr. Pyott also said he believes shareholder support for a special meeting in December where Mr. Ackman will seek to unseat the majority of the company's board reflects shareholders' desire to adhere to the best corporate governance practices, and not support to remove the directors.
In response, in Valeant's latest letter, dated Wednesday, Mr. Pearson again said Allergan's concerns about its business model are unfounded as he offered the third-quarter guidance and added he remains convinced Allergan's shareholders would support a combination.
A representative from Allergan on Wednesday wasn't available to confirm the veracity of the letter or comment on Valeant's latest missive.
In their ongoing war of words, Valeant has criticized Allergan's management for spending too freely. Allergan, meanwhile, has said Valeant's cost-cutting would threaten future sales growth and research and development, putting the company at risk.
Meanwhile, in a move that could thwart Valeant's efforts, Allergan has plotted a takeover of its own and is in late-stage talks with North Carolina-based Salix Pharmaceuticals Ltd.
The new guidance boosted Valeant's stock on Wednesday, which was enjoying one its best days of the year while also driving up the value of its Allergan offer.
Valeant shares were up 7.8% to $124.97 in recent trading and earlier reached above $127. At the day's high, Valeant's latest offer for Allergan would have been worth nearly $178 a share, close to the important threshold of $180 a share that Valeant and Mr. Ackman have said would entice Allergan shareholders.
Allergan shares were up 3.9% to $175.74. http://on.wsj.com/1DyzOQQ